(GLP-1) receptor agonists are increasingly prescribed for the management of type 2 diabetes and, more recently, for obesity treatment in populations without diabetes
Across six randomized, double-blind, placebo-controlled trials, AOD-9604 showed no effect on serum IGF-1, no impairment of glucose tolerance, and no insulin resistance all common problems with full GH therapy (Stier et al., 2013)
The honest answer is that licensed product cannot legally be bought that way
For instance, models with active malignancies (such as pituitary adenomas or breast cancer) face risks from increased growth hormone (GH) stimulation, which could exacerbate disease progression
In addition, it may contain information that differs from that shown here
Register now Join the community